Fund moves
4.6%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 30, 2026 · Filed Nov 4, 2026
A Ligand Pharmaceuticals director sold $16K of Ligand Pharmaceuticals shares. The filing references vesting of compensation awards.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$15,887
Shares × reported transaction price
1 day after results of Oct 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $322.75 on Oct 30, 2026, at its 52-week high, after a 14% rise over the previous 30 trading days
52-week range $181.65 (Feb 12, 2026) to $322.75 (Oct 30, 2026), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $283.49 on Sep 18, 2026. Describes the past only, not a forecast
RSI 63, 28% above its 200-day average, 9% above its 50-day average, at the 52-week high, 20-day volatility 32% a year, against the S&P 500: +8 points over 1 month, +11 points over 3 months, +36 points over 6 months
From the adjusted closes up to Oct 30, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.2% | −0.9% | +1.1% |
Past results only. Not a forecast.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider selling
Traded Nov 12 · filed 4 days laterNot reported under a pre-arranged trading plan
A Ligand Pharmaceuticals director sold $636K of Ligand Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
John W Kozarich (Director) sold ~$163K of Ligand Pharmaceuticals, Inc.
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.